The journey from cancer diagnosis to treatment with hematopoietic stem cell transplantation (HSCT) is a complex, costly, and multifaceted process influenced by various factors that shape the course of patient care. HSCT is particularly susceptible to racial, socioeconomic, and geographic disparities in access and outcomes, given its specialized nature and limited availability in just about 200 U.S. cancer centers.

More than 40% of patients receiving antibody-drug conjugates (ADCs) will experience ocular toxicities during treatment, ONS members Caroline Clark, MSN, APRN, OCN^®, AGCNS, EBP-C, and Ikuko Komo, MSN, CNS, NP, AOCNS^®, AOCNP^®, reported in an article in the April 2024 issue of the Clinical Journal of Oncology Nursing.

Complex cancer treatments like bispecific antibodies and chimeric antigen receptor T-cell therapy are associated with equally complex side effects and complications. When patients experience signs and symptoms back home away from their dedicated cancer care team, how should they seek intervention? Should they go to the emergency room? The local urgent care facility? Call 9-1-1? And, if they do any of those things, will the healthcare providers in those settings know how to care for them?

Lynch syndrome, now referred to as hereditary nonpolyposis colorectal cancer (HNPCC), was first identified in a family in 1895. In 1966, Henry Lynch discovered a series of families with colon and other cancers in Nebraska. Today, the evidence demonstrates that HNPCC is associated with germline pathogenic variants in the MLH1, MSH2, MSH6, PMS2, and EPCAM genes, which are mismatch repair (MMR) genes.